Same Advice Was Given in 2019
microwavenews.com, 13 April 2024
An advisory group to the International Agency for Research on Cancer (IARC) has —once again— recommended a new assessment of the cancer risk posed by RF radiation. RF is one of about a hundred agents listed as “high priority” for evaluation over the next five years, 2025-2029.
The panel, made up of 28 independent scientists from 22 countries, met last month in Lyon, France (IARC’s hometown), to consider more than 200 agents that had been nominated for evaluation or reevaluation. The panel’s recommendations were announced yesterday in the news section of Lancet Oncology and an IARC press release.
Others on the high-priority list include acetaminophen (Tylenol), methamphetamine, bisphenols, hair dyes, the hepatitis D virus and smoking cannabis. The full list is below.
RF was deemed to be less urgent than most of the others on the list. In a footnote, the panel advised that it and a small number of the other high-priority agents (for instance, GLP-1 analogs and cannabis smoking) should not be reviewed until the second half of the five-year period, that is, not until late 2027, at the earliest.
Even so, IARC cannot possibly evaluate all those nominated as high priority. Each review is long and expensive: A panel of experts must prepare a comprehensive analysis which is later published as a Monograph. When completed, a Monograph typically runs hundreds of pages and includes a vast number of references. The agency can only address a small proportion of the recommended agents over a five-year period.
Elisabete Weiderpass, the director of IARC, and her staff will decide which ones make the cut.
In May 2011, an IARC committee evaluated RF at an eight-day meeting in Lyon and found the radiation to be a possible human carcinogen. (IARC’s RF Monograph was published in 2013.)
Continue reading:
https://microwavenews.com/news-center/iarc-again-advised-review-rf-cancer-risk
The panel, made up of 28 independent scientists from 22 countries, met last month in Lyon, France (IARC’s hometown), to consider more than 200 agents that had been nominated for evaluation or reevaluation. The panel’s recommendations were announced yesterday in the news section of Lancet Oncology and an IARC press release.
Others on the high-priority list include acetaminophen (Tylenol), methamphetamine, bisphenols, hair dyes, the hepatitis D virus and smoking cannabis. The full list is below.
RF was deemed to be less urgent than most of the others on the list. In a footnote, the panel advised that it and a small number of the other high-priority agents (for instance, GLP-1 analogs and cannabis smoking) should not be reviewed until the second half of the five-year period, that is, not until late 2027, at the earliest.
Even so, IARC cannot possibly evaluate all those nominated as high priority. Each review is long and expensive: A panel of experts must prepare a comprehensive analysis which is later published as a Monograph. When completed, a Monograph typically runs hundreds of pages and includes a vast number of references. The agency can only address a small proportion of the recommended agents over a five-year period.
Elisabete Weiderpass, the director of IARC, and her staff will decide which ones make the cut.
In May 2011, an IARC committee evaluated RF at an eight-day meeting in Lyon and found the radiation to be a possible human carcinogen. (IARC’s RF Monograph was published in 2013.)
Continue reading:
https://microwavenews.com/news-center/iarc-again-advised-review-rf-cancer-risk
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.